期刊
JAPANESE JOURNAL OF INFECTIOUS DISEASES
卷 75, 期 4, 页码 398-402出版社
NATL INST INFECTIOUS DISEASES
DOI: 10.7883/yoken.JJID.2021.751
关键词
-
资金
- Ministry of Health, Labour and Welfare, Japan [10110400, 21HA2003]
- JSPS KAKENHI [JP18K10036]
Avian influenza A viruses, including H5N1, H5N2, H5N8, H7N7, H7N9, H9N1, and H9N2, isolated in Japan have been found to be susceptible to neuraminidase and RNA polymerase inhibitors, indicating that these drugs could be effective treatment options for human avian influenza infections.
The circulation of avian influenza A viruses in poultry is a public health concern due to the potential transmissibility and severity of these viral infections. Monitoring the susceptibility of these viruses to antivirals is important for developing measures to strengthen the level of preparedness against influenza pandemics. However, drug susceptibility information on these viruses is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: an M2 inhibitor (amantadine), neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir) and RNA polymerase inhibitors (baloxavir and favipiravir). Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess phenotypic viral susceptibility to drugs have revealed that these avian influenza A viruses are susceptible to neuraminidase and RNA polymerase inhibitors. These results suggest that neuraminidase and RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据